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Abstract
Objectives We present our single-centre experience with
the direct flow medical (DFM) trans-catheter aortic valve
implantation (TAVI) prosthesis addressing the impact of
learning curve upon outcomes.
Background The DFM has been recently introduced for
TAVI. The prosthesis presents original design and implan-
tation features.
Methods Patients were divided into three groups according
to the chronological implantation sequence that reflected
technical skills acquisition of the entire team.
Results Group I included the first 20 patients (early learn-
ing phase), group II the second 20 patients (proctoring to
other members of the team), and group III the follow-
ing 93 patients (technique consolidation). Differences in
baseline and procedural variables were analysed. Nonpara-
metric correlation and linear regression were used to iden-
tify changes according to institutional cumulative experi-
ence. There was a significant correlation between catheter-
isation time and institutional experience (rho = –0.4; p <
0.0001) confirmed at linear regression (beta = –0.2; p =
0.001; CI: –0.3 – –0.08). Moreover, there was lower rate of
valve retrieval in group III (15% vs. 20% vs. 10%; p = 0.5).
No intra-procedural mortality was reported and improved
early safety (at 30 days) was observed (80% vs. 85% vs.
87.1; p = 0.7). At hospital discharge, valve haemodynamic
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performance was satisfactory with only mild regurgitation
in 10% (I), 20% (II), and 9.7% (III) (p = 0.8).
Conclusions DFM adequate sizing and implantation can
be achieved after the early learning phases. A significant
reduction in catheterisation time is reported after the first
20 patients. Results remain satisfactory during the proctor-
ing and technical consolidation phase.
Keywords Trans-catheter aortic valve implantation ·
Percutaneous · Learning curve
Introduction
In the present manuscript we summarise our experience
with a recently introduced inflatable and fully retrievable
metal-free transcatheter aortic valve implantation (TAVI)
prosthesis (Direct Flow Medical, DFM, Santa Rosa, Cal-
ifornia, USA) focusing on our institutional learning curve
and its impact on patient selection, intraoperative variables,
and postoperative outcomes.
Methods
Perioperative data were prospectively collected in a series
of patients undergoing TAVI with the DFM prosthesis. Pa-
tients had previously signed informed consent to the pro-
cedure and to clinical data handling for scientific purposes.
Data were reported according to the Valve Academic Re-
search Consortium definitions (VARC-2) [1].
The design features of this bovine pericardial prosthesis
have already been described in the literature [2, 3]. The
prosthesis includes three pericardial leaflets mounted on
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Table 1 Demographic, clinical and anatomic characteristics of patients
Group I (20) Group II (20) Group III (93) p-value
Age (years) 80.3 ± 5.9 79.6 ± 5.2 80.9 ± 5.4 0.6
Gender-Female 40.0% 50.0% 35.5% 0.5
BMI 28.0 ± 5.1 28.1 ± 4.5 28.1 ± 10.9 1.0
Log. euroSCORE 22.9 ± 12.5*
(20.1; 6.6–44.0)




















LVEF (%) 49.4 ± 13.4 57.3 ± 12.4 52.5 ± 14.5 0.02
AV gradient mean (mm Hg) 42.5 ± 13.7 49.8 ± 12.9*** 40.7 ± 14.2*** 0.04
AVA (cm2) 0.71 ± 0.1 0.65 ± 0.1 0.74 ± 0.1 0.4
Cardiac CT
LVOT eccentricity index 0.26 ± 0.08 0.29 ± 0.08 0.28 ± 0.08 0.3
LVOT perimeter derived diameter (mm) 24.9 ± 1.6 24.0 ± 1.4 25.2 ± 2.5 0.07
Annulus aortic eccentricity index 0.20 ± 0.09 0.23 ± 0.09 0.22 ± 0.08 0.3
Annulus perimeter derived diameter (mm) 24.7 ± 1.5 24.1 ± 1.4 25.2 ± 2.2 0.07
Calcification total extension (mm) 14.5 ± 4.2**** 12.3 ± 3.5 11.5 ± 3.6**** 0.005
*p < 0.05; ** p < 0.05; *** p < 0.05; **** p < 0.005
BMI body mass index; Log. EuroSCORE Logistic EuroSCORE; STS-Score(M) Society of Thoracic Surgeons Mortality Risk Score;
TEE transoesophageal echocardiography; AV-gradient mean mean aortic transvalvular gradient; AVA aortic valve area; CT computerised
tomography; LVOT left ventricular outflow tract; Eccentricity Index ((Diameter max-Diameter min)/(Diameter max)); calcification total extension,
from LVOT towards aortic bulbus
and upper ring connected by lateral struts. Three hollow
wires for valve pressurisation and fine-tuned positioning
are screwed to the upper ring. The valve is mounted on
a flexible 18-F delivery system.
All patients included in this series had been diagnosed
with severe symptomatic aortic valve stenosis. Valve siz-
ing was performed on the basis of the preoperative cardiac
computed tomography (CT) imaging. Pure aortic insuffi-
ciency, previous aortic valve surgery (replacement/repair),
and previous TAVI were excluded from the present analysis.
To assess the learning process and its impact upon patient
selection, intra-procedural results and hospital outcomes,
we divided the entire cohort of patients treated by our TAVI
team with the DFM into three groups, according to the
chronological sequence of implantation, which reflects de-
vice amelioration and technical skills acquisition/evolution
for the entire TAVI team. Group I included the first 20 pa-
tients and was defined as the early learning phase. Only
two operators in our team were involved in this phase and,
at that point, only two valve sizes were available (25 and
27 mm) and an early version of the DFM delivery catheter
was used. Group II included the second 20 patients and
was defined as the proctoring to other members of the team
phase. At that stage new members of the team (in total
two new members) were introduced to the DFM system,
an implemented delivery catheter was produced, and an
extra size for the DFM prosthesis was available (23 mm).
Group III included the remaining and following 93 patients
and was defined as the phase of technique consolidation
and improvement.
The effect of the learning curve was assessed by pro-
cedure time efficiency (operating time, catheterisation time
from valve sheath introduction in the femoral artery to its
removal and fluoroscopy time) and by outcomes (intra-pro-
cedural and 30-day).
Differences between the three groups were tested by
means of one-way analysis of the variance (ANOVA)
followed by post-hoc Tukey test (to define differences
in between groups), and chi-square and Fisher’s exact
tests whenever appropriate. Nonparametric correlation
(Spearman rho) and linear regression were used to identify
changes according to institutional cumulative experience.
The statistical calculations were run using the SPSS (ver-
sion 22) software.
Results
A total of 133 patients with symptomatic severe aortic
valve stenosis were treated; the first 20 were included in
group I, the second 20 in group II, and the following 93 in
group III. Table 1 summarises the preoperative data in the
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Table 2 Procedural, morbidity, and mortality data
Group I (20) Group II (20) Group III (93) p-value
Procedure time, min 110.1 ± 42.3* 96.8 ± 35.9 90.8 ± 30.8* 0.08
Catheter time, min 56.9 ± 38.7**, *** 35.1 ± 11.8** 34.0 ± 22.5*** 0.001
Contrast, ml 99.0 ± 51.7a 134.3 ± 47.8 152.8 ± 110.5a 0.08
Radiation time, min 23.5 ± 13.2 27.4 ± 16.3 22.9 ± 11.4 0.4
Radiation dose-area product, µGcm2 10303.9 ± 6193.3 13083.9 ± 9830.8 13202.3 ± 11857.6 0.6
Access management 0.2
Percutaneous 100.0% 95.0% 87.1%
Cut-down 0.0% 5.0% 12.9%
Implanted prosthesis size-average, mm 26.1 ± 1.0 25.5 ± 1.1 26.1 ± 1.7 0.2
DF 23 – 5.0% 8.6%
DF 25 45.0% 65% 39.8%
DF 27 55.0% 25.0% 33.3%
DF 29 – – 15.1%
CV 26 – 5.0% 1.1%
CV 31 – – 2.2%












Percutaneous 75.0% 70.0% 79.6%
Stent 25.0% 15.0% 2.2%
Hospitalisation after procedure, days 14.0 ± 10.9+, © 8.3 ± 2.8+ 9.1 ± 5.9© 0.009
All-cause mortality 10.0% 10.0% 6.5% 0.7
Cardiovascular 5.0% 10.0% 3.2%
Non-cardiovascular 5.0% 0.0% 3.2%
Myocardial infarction 5.0% 0.0% 0.0% 0.3
Stroke 5.0% 0.0% 3.2% 0.5
Life-threatening or disabling bleeding 5.0% 0.0% 1.1% 0.03
Major bleeding 15.0% 5.0% 2.2% 0.03
Major vascular complication 0.0% 5.0% 1.1% 0.05
New pacemaker 25.0% 15.0% 13.0% 0.6
Device successb 90.0% 75.0% 90.3% 0.6
Early safety (at 30 days)b 80.0% 85.0% 87.1% 0.7
*p = 0.07; **p < 0.05; ***p < 0.05; ap = 0.07; ||p < 0.05; #p < 0.05; +p < 0.05; ©p < 0.05
bAs defined by VARC criteria
three groups. Intra-procedural findings are summarised in
Table 2.
With experience there was a reduction in procedural and
radiation time with a positive trend in the total use of con-
trast (Table 2). Catheterisation time (the time elapsing
from introduction to removal of the valve delivery sys-
tem) was significantly reduced from group I to group III
(p = 0.001). In addition, there was a significant correlation
between catheterisation time and institutional experience
(rho = –0.4; p < 0.0001) (Fig. 1), which was confirmed at
linear regression (beta = –0.2; p = 0.001; CI: –0.3 – –0.08).
When looking at the overall DFM retrieval and pull
through rate, this was not significantly lower in group III
(p = 0.4). In four cases (1 in group II and 3 in group III)
Medtronic CoreValves (Minneapolis, Minnesota, USA)
were implanted after having uneventful retrievals of the
DFM prostheses. In one case the DFM catheter was kinked
and fractured twice as a result of a very tortuous and calci-
fied iliac-femoral access. In a second case the DFM could
not be inflated within a small and hypertrophic left ven-
tricle, possibly as a result of entanglement with the mitral
sub-valvular apparatus. In two other cases with large aortic
annuli (29 mm) and limited aortic calcifications, 31 mm
Medtronic CoreValves were implanted after failed attempts
at implanting the largest DFM (29 mm) prosthesis. No
patients required emergent thoracotomy and/or conversion
to conventional aortic valve replacement.
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Fig. 1 Correlation between
catheterisation time, procedural
time, radiation time (Y-axis) and
institutional experience (Y-axis:
minutes and X-axis: numbers of
implanted valves)
Total hospitalisation was significantly reduced through-
out the experience (p = 0.009) and lower (non-significant)
total and cardiovascular in-hospital mortality was reported
in group III (Table 2). No mortality was directly related to
the DFM prosthesis. Apart from one case, all ten deceased
patients had a very complex preoperative comorbid profile
including frailty and advanced age (81–94 years) in seven
patients, depressed LVEF <30% in three patients, and dial-
ysis in one patient. Vascular bleeding occurred significantly
more often in the early phases of the experience (p = 0.03).
There was no statistically significant difference in device
success and early safety according to VARC criteria [1] in
the three groups. There was a higher device success rate
in the very early and last phases. Moreover, a higher early
safety was reported in the last phase of our learning curve
(Table 2).
Pre-discharge echocardiography data are summarised in
Table 3. Although higher (non-significant) trans-prosthetic
gradients were observed in the late phase, mild prosthetic
aortic valve stenosis [1] (mean prosthetic gradient between
20–40 mm Hg and peak velocity between 3–4 m/s) occurred
at discharge in 2 patients in group I (10%), 4 patients in
group II (21.1%), and in 6 patients in group III (6.7%) (p =
0.6).
Discussion
This metal-free, inflatable, fully retrievable, and reposition-
able valve offers some original and potentially advanta-
geous features which, even within the premises of centres
with recognised wide experience with other TAVI devices,
can be appreciated only through an initial learning phase.
In a recent prospective multicentre trial of the DFM,
a preplanned roll-in cohort of three patients per site was
accepted as the necessary number to allow the operator
to gain technical expertise with this new technology [3].
The 20-patient limit we have proposed to define the first
and second phases of learning reflects what happened in
our practice and in the skills acquisition process within our
facility.
We would like to remark on the importance of dis-
tinguishing two different stages in the learning process:
first the patient selection stage and second the implanta-
tion (technical) stage. As new prostheses are introduced
into the market, operators should be prepared to treat aor-
tic stenosis using a patient-tailored approach that should
be based upon the peculiar valve design and the different
anatomical scenarios that may be encountered. In fact, dur-
ing the same period we treated over 100 patients with other
TAVI prostheses.
In particular, extension and distribution of aortic calci-
fication has played an important role in guiding prosthesis
selection. With time we have developed a structured selec-
tion algorithm that takes the DFM design and the specific
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Table 3 Postoperative echocardiographic data (through 30 days)
Group I (20) Group II (20) Group III (93) p-value
LVEF (%) 52.8 ± 11.4 59.6 ± 16.1 54.7 ± 14.1 0.4
Max gradient, mm Hg 27.4 ± 11.7 26.8 ± 8.8 28.8 ± 12.8 0.8
Mean gradient, mm Hg 12.7 ± 6.5 14.6 ± 6.5 16.1 ± 7.0 0.2
Peak velocity, m/s 2.8 ± 0.6 2.5 ± 0.7 2.7 ± 0.6 0.5
Transvalvular (central) regurgitation 0.6
None 90.0% 80.0% 88.2%
Mild 10.0% 20.0% 11.8%
Paravalvular regurgitation 0.4
None 90.0% 80.0% 90.3%
Mild 10.0% 20.0% 9.7%
Total aortic regurgitation 0.8
None 90.0% 80.0% 84.9%
Mild 10.0% 20.0% 15.1%
characteristics of the patient’s aortic unit into consideration.
The DFM has a minimised traumatic effect on the native
tissues, as a result of its metal-free structure and contained
radial force. The valve design includes an annulus to aor-
tic ring height of 15 mm (for the 23, 25, 27 mm valves)
to 16 mm (for the 29 mm valve) and ideally the prosthe-
sis height should overcome and ‘embrace’ the total vertical
extension (across the annulus of the aortic valve) of the cal-
cification to allow complete and symmetric expansion of the
upper ring of the prosthesis. Moreover, having a landing
zone for the lower ring of the prosthesis that is free from
calcifications will enhance sealing and minimise the risk
of paravalvular leak. With this concept in mind, whenever
bulky calcifications are extending continuously and unin-
terruptedly from the aortic annulus into the left ventricular
outflow tract (LVOT) for a total depth of >3 mm, we prefer
to use a different TAVI prosthesis (with a stronger radial
force), to reduce the risk of paravalvular leak.
These concepts are substantiated in our results section
where it emerges that, throughout our overall experience,
the average calcification vertical extension (from the LVOT
to the aortic bulbus) is constantly and significantly reduced
from an average of 14.5 mm, in the initial phase, to the
most recent value of 11.5 mm. This selection strategy has
allowed us to eliminate the occurrence of moderate par-
avalvular leak and to reduce the rate of mild regurgitation
to below 10%.
For what concerns our implantation technique, we have
to report a constant evolution. In fact through the three
phases of our institutional learning curve we have modi-
fied and optimised the implantation technique of this newly
introduced prosthesis. In the last phase of our experience
we consistently applied a modified technique for DFM im-
plantation that includes an initial ‘low-pressure’ inflation
of the valve followed by a patient tailored technique for
valve positioning (alternate curve technique), according to
the calcification distribution within the aortic unit. Both
modifications have been described previously [4].
Optimisation of the DFM implantation technique is re-
flected in a significant reduction in catheterisation time dur-
ing the learning process, as confirmed by our correlation
and linear regression analysis. The increased use of con-
trast agent that emerges from our data deserves a comment
apart. This finding most probably results from the fact that
as experience grew, we dedicated more attention to optimis-
ing the final position of the DFM prosthesis and collecting
intraoperative imaging for research purposes.
Moreover, as we gained experience with the valve intrac-
ardiac navigation we also reduced our prosthesis retrieval
and pull-through rates. The 10.8 and 7.5% retrieval and
pull-through rates that we observed in the last phase of our
experience are in line with those proposed in the prospective
trial [3]. We have also started to treat patients with border-
line anatomical features that we would have not treated in
the very early stages. By testing the possible boundaries of
this technology we have at times also incurred failures, even
in the last phase of our learning curve. In four cases, this
resulted in full retrieval of the DFM and successful implan-
tation of a different device. Although we were perfectly
aware of the anticipated difficulties (tortuous iliac-femoral
axis, extremely hypertrophic and small ventricle, large and
only slightly calcified aortic annulus) in all four cases, we
decided to proceed with the DFM implantation. The deci-
sion was guided by the fact that certain anatomical features
are difficult to approach with any TAVI prostheses and we
were aware of the fact that eventual DFM retrieval could
have been performed at any time, maintaining perfectly sta-
ble haemodynamic conditions and without compromising
the final outcome.
A contained paravalvular regurgitation rate has been re-
ported at echocardiography since the beginning of our ex-
perience with the DFM valve. Our findings are very encour-
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aging and are in line with those reported in the multicentre
trial [3]. In the last part of our experience we reported
a post-procedural mean trans-prosthetic gradient value of
16.1 mm Hg, which is slightly higher than the 12.7 mm Hg
gradient documented in the initial phase of our experience.
Although a mean gradient of 12.6 mm Hg has been reported
in the DFM prospective trial, it is not clear if this mean
value also included evaluations performed intraoperatively,
under general anaesthesia [3]. The increased mean gradient
we have reported may have resulted from the introduction
of the 23 mm DFM prosthesis. This prosthesis size only
became available at the second stage and, in fact, even
in the prospective trial no patients were treated with the
23 mm DFM [3]. In addition, other authors have recently
documented a discrepancy between invasive and echocar-
diographic transvalvular gradient measurements after DFM
implantation [5].
Moreover, in a recent propensity matched study compar-
ing the DFM prosthesis with the Medtronic CoreValve and
Edwards Sapien XT (Edwards Lifesciences, Irvine, Cali-
fornia, USA), Zhang et al. demonstrated similar immediate
postoperative trans-prosthetic gradients with the three dif-
ferent prostheses [6].
With experience we have witnessed a decrease in the
length of hospitalisation, major morbidity, permanent pace-
maker implantation rate, and in-hospital mortality. In ad-
dition, even in the more recent part of our experience we
reported an early safety at 30-days [1] of 87.1%. We are
aware that this value is lower than the 91% rate reported
in the prospective trial [3]. The difference is mainly due
to the higher 30-day mortality rate (6.5% vs. 1.3%) that
we experienced. We have to remark that the cardiovascu-
lar mortality was 3.2% in group III and that, in the overall
experience, none of the deaths were peri-procedural and/or
directly related to the prosthesis implantation and to its
function. Finally, as already elucidated in the results sec-
tion, most of the deaths occurred in elderly and comorbid
patients.
Conclusions
Because of its original design and implantation technique,
TAVI with the DFM has a learning phase. Although ad-
equate patient selection and valve implantation can be
achieved after the early learning phases, results were im-
proved with the evolution of our learning process.
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